Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib
Open Access
- 14 May 2013
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 27 (10) , 2075-2077
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Circulating plasma cells predict the outcome of relapsed or refractory multiple myelomaLeukemia & Lymphoma, 2012
- Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3Blood, 2011
- Factors Influencing the Abundance of the Side Population in a Human Myeloma Cell LineBone Marrow Research, 2011
- Proteasome inhibitors in the treatment of multiple myelomaLeukemia, 2009
- CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapyBlood, 2009
- A Transgenic Mouse Model of Plasma Cell Malignancy Shows Phenotypic, Cytogenetic, and Gene Expression Heterogeneity Similar to Human Multiple MyelomaCancer Research, 2007
- Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomibBlood, 2006
- Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)–dependent migration and homing in multiple myelomaBlood, 2006
- Plasma-cell homingNature Reviews Immunology, 2003
- A Phase 2 Study of Bortezomib in Relapsed, Refractory MyelomaNew England Journal of Medicine, 2003